On February 23, 2024 Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, reported positive data on its lead investigational high-precision cell therapy, Orca-T, presented at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) (Press release, Orca Bio, FEB 23, 2024, View Source [SID1234640425]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC). Within the non-randomized cohorts of varying conditioning regimens and disease types, Orca-T demonstrated favorable results across clinical outcomes including relapse-free survival (RFS), non-relapse mortality (NRM) and overall survival (OS).
"When treating hematological malignancies, physicians are often faced with compromising between the risk of relapse and the risk of serious toxicities, all of which can impact overall patient survival," said Alexandra Gomez-Arteaga, MD, Assistant Professor of Medicine at Weill Cornell Medicine, hematologist oncologist in the Bone Marrow Transplant and Cellular Therapy Program at NewYork-Presbyterian/Weill Cornell Medical Center, and presenting author. "While advances in prophylaxis agents have demonstrated improvements in reducing the rate of graft versus host disease, the findings of this retrospective analysis suggest Orca-T may also provide benefits across key survival metrics, further highlighting the importance of identifying novel approaches that may offer enhancements across all patient outcomes."
The analysis further compared a subgroup of 48 patients from Orca Bio’s multi-center Phase 1b trial who received a MAC Orca-T with single-agent tacrolimus (TAC) and a conditioning regimen of busulfan, fludarabine and thiotepa (BFT) which is being used in the pivotal Phase 3 clinical study of Orca-T, with 61 patients from the CIBMTR literature-based cohort1 who received an alloHSCT with a combination of PTCy, calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF). The analysis included patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who had a median follow-up time of 15 months and 12 months in the Orca-T and PTCy cohorts, respectively. The outcomes at 12 months are summarized in the table below:
Orca-T with BFT/TAC
Standard alloHSCT with CNI/MMF/PTCy
RFS
86%
63%
NRM
0%
17%
OS
100%
76%
In a second oral presentation, results were shared from a subgroup analysis of Orca Bio’s ongoing multi-center Phase 1b clinical trial of patients with AML, MDS and acute lymphocytic leukemia (ALL) who received Orca-T and BFT conditioning. The findings demonstrated Orca-T’s potential ability to deliver similar outcomes in older patients (55+ years of age, n=25) and younger patients (18-54 years of age, n=39) undergoing MAC. Notably, Orca-T delivered similar results across RFS (84.8% in younger patients and 82.3% in older patients), NRM (0% in both groups) and OS (100% and 95.5% in the younger and older patient groups, respectively). Across all patients, Orca-T continued to be manufactured reliably and delivered with vein-to-vein times of 72 hours or less across the U.S. These data were previously presented at the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December 2023.
"We are pleased to present findings that reinforce the potential for Orca-T to address the balancing act that providers encounter when working to achieve a lasting cure while reducing toxicities," said Scott McClellan, MD, PhD, Chief Medical Officer at Orca Bio. "The ability of Orca-T to potentially treat the disease while also lowering treatment-related mortality, including for patients of a more advanced age, could arm physicians with an important new therapeutic option. We look forward to continued investigation of Orca-T in our randomized Phase 3 study, Precision-T."
About Orca-T
Orca-T is an investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies. Orca-T includes infusions containing regulatory T-cells, CD34+ stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors. Orca-T is currently being evaluated in a pivotal Phase 3 clinical trial at leading transplant centers across the U.S. and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.